by Ben Adams Jan 29, 2020

Algernon Pharmaceuticals has chosen contract research organization Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic cough trial for its experimental med NP-120 (Ifenprodil).

The study is slated to start in the next quarter, and Algernon will tap Novotech’s experience across the Asia-Pacific region. In addition, the CRO has penned a letter of intent to make an equity investment in Algernon worth around CA$220,000.